Charles Schwab’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Charles Schwab’s Portfolio ENZN Stock Details ENZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-21,300	Closed	-$11K	–	3195
2016 Q1	$11K	Hold	21,300	–	–	﹤0.01%	3053
2015 Q4	$15K	Hold	21,300	–	–	﹤0.01%	3092
2015 Q3	$21K	Hold	21,300	–	–	﹤0.01%	3079
2015 Q2	$26K	Hold	21,300	–	–	﹤0.01%	3080
2015 Q1	$23K	Hold	21,300	–	–	﹤0.01%	3075
2014 Q4	$24K	Hold	21,300	–	–	﹤0.01%	3101
2014 Q3	$24K	Hold	21,300	–	–	﹤0.01%	3064
2014 Q2	$23K	Sell	21,300 -58,000	-73%	-$55.3K	﹤0.01%	3081
2014 Q1	$82K	Hold	79,300	–	–	﹤0.01%	3047
2013 Q4	$92K	Sell	79,300 -238,920	-75%	-$368K	﹤0.01%	3062
2013 Q3	$557K	Sell	318,220 -91,580	-22%	-$169K	﹤0.01%	2507
2013 Q2	$779K	Buy	+409,800	New	+$1.2M	﹤0.01%	2296

Other funds holding ENZN

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

OSAM

O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return

MCM

Monarch Capital Management Fort Wayne, Indiana $436M AUM 26.61% 1-Year Est. Return

CFA

CT Financial Advisors Chadds Ford, Pennsylvania $162M AUM 9.58% 1-Year Est. Return

Charles Schwab's ENZN Position: Q2 2016 in Review

Charles Schwab sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q2 2016, closing a stake of 21,300 shares — an estimated $11K sold.

Charles Schwab first reported a position in ENZN in Q2 2013 and held it in 12 quarters. The position peaked at $779K in Q2 2013. 10 funds tracked by Wall St. Rank hold ENZN as of Q2 2016.

Charles Schwab reported no remaining ENZON PHARMACEUTICALS INC position as of Q2 2016 after selling out during the quarter.
Charles Schwab sold 21,300 ENZON PHARMACEUTICALS INC shares in Q2 2016, an estimated $11K.
Charles Schwab first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 12 quarters.
Charles Schwab's ENZON PHARMACEUTICALS INC position peaked at $779K in Q2 2013.
10 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q2 2016.

Based on Charles Schwab's 13F filing for Q2 2016, filed 15 Aug 2016.